Clinical significance of angiotensin converting enzyme (ACE) activity in sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 384s Year: 2001
The effect of angiotension converting enzyme inhibitors on the production of TGF-β from fibroblast Source: Eur Respir J 2006; 28: Suppl. 50, 227s Year: 2006
Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population Source: Eur Respir J 2006; 27: 1217-1222 Year: 2006
Bronchial reactivity for histamine and serum angiotensin converting enzyme (sACE) activity in sarcoidosis patients Source: Eur Respir J 2004; 24: Suppl. 48, 669s Year: 2004
No association of angiotensin I-converting enzyme gene polymorphism and pulmonary function in cystic fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 173s Year: 2003
Activity and phenotypes of angiotensin-converting enzyme (ACE) in sarcoidosis with various organ involvement Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020
Etiology specific reductions in pulmonary endothelial angiotensin converting enzyme activity in patients with PAH Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006
Effect of angiotensin converting enzyme (ACE) gene polymorphism on diaphragmatic endurance in neonates Source: Annual Congress 2008 - Neonatal intensive care: ventilation and beyond Year: 2008
The role of angiotensin converting enzyme gene polymorphism in pulmonary thromboembolism Source: Annual Congress 2004 - Pulmonary embolism Year: 2004
Association of circulating angiotensin converting enzyme activity with respiratory muscle function in infants Source: Annual Congress 2010 - Paediatric and neonatal intensive care Year: 2010
ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin Source: Eur Respir J 2008; 31: 363-371 Year: 2008
ACE I/D but not AGT (-6)A/G polymorphism is a risk factor for mortality in ARDS Source: Eur Respir J 2007; 29: 482-488 Year: 2007
Impact of statins, angiotensin-converting enzyme inhibitors (ACEI), and angiotensin receptor blockers (ARBS) on reducing COPD morbidity Source: Annual Congress 2009 - Treatment of airways disease Year: 2009
Alteration in angiotensin-converting enzyme 2 by PM1 during the development of emphysema in rats Source: ERJ Open Res, 6 (4) 00174-2020; 10.1183/23120541.00174-2020 Year: 2020
Impact of statins, angiotensin-converting enzyme inhibitors(ACEI), and angiotensin receptor blockers (ARBs) on reducing COPD morbidity Source: Annual Congress 2010 - COPD: management Year: 2010
Serum angiotensin converting enzyme (ACE) as additional clinical markers of activity of pulmonary and extra-pulmonary locations of sarcoidosis Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders Year: 2011
Ghrelin effects on local renin angiotensin from pulmonary vessels Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011
Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients Source: ERJ Open Res, 7 (1) 00848-2020; 10.1183/23120541.00848-2020 Year: 2021
Effects of angiotensin-converting enzyme inhibitor on peripheral skeletal muscle dysfunction in emphysematous rats Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008
Effects of endothelial nitric oxide synthase enzyme, angiotensin converting enzyme and serotonin transporter genotypes on pulmonary hypertension in COPD Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010